Developing successful strategies to avoid contamination, optimise clearance and ensure maximal viral safety

Contaminations in both Baxter and Genzyme biological products in 2009, and the porcine circovirus contamination of GSK’s Rotarix vaccine in March of this year has highlighted the issue of viral safety in biologics more than ever before.

Pharma IQ’s Ensuring Viral Safety and Clearance in Biologics conference will help dissect this polemic and facilitate discussion between like-minded professionals within the field, presenting industry professionals with a forum for learning new developments and the networking potential to forge lasting business relationships.

Join us in Munich to discuss key and contemporary topics surrounding viral and pathogen safety in the biotech and biopharmaceutical industry.

What would you do in the case of a virus breakout in your manufacturing plant?

Put your heads together with contemporaries in the industry and fashion a quick and ready response to the question and a strategy to deal with the aftermath. All comers welcome and outside-the-box thinking encouraged on ways to tackle and minimise the scope of a very real threat!

feature-banner

International experts already include:

  • MPlavsic Mark Plavsic
    Senior Director, Gene Therapy Development
    Genzyme
  • KMurray Kristin Murray
    Senior Manager GCMC Regulatory
    Pfizer
  • Hans-Rogl Hans Rogl
    Manager Development Recovery & Downstream Processing
    Roche Diagnostics
  • Viral-and-TSE Marc Martin
    Viral Safety Assessor
    AFSSAPS

Industry representatives from across the globe will discuss how to:

  • Apply crucial aspects of international viral safety regulations to speed approval and time to market
  • Ensure effective viral clearance using the latest techniques and studies to optimise your procedures:
  • Optimise your testing processes and guarantee viral and pathogen safety in your stocks
  • Enhance your virus safety framework utilising cutting-edge QRM tools and most effective methods to implement them
  • Elucidate the procedures and processes involved in optimal viral clearance for viral agent products
  • Save money and enhance viral safety through the application of single-use technology in your bioprocesses
  • Learn from the aftermath of Genzyme’s Allston Landing plant contamination from Genzyme themselves

Featuring two pre-conference workshops with top industry professionals!

A: Detecting mycoplasma utilising rapid testing methods

B: The best practice and better business case for adventitious agents testing with CTOs

How would you respond to a contamination?

Don’t miss our interactive SCENARIO ANALYSIS SESSION which will give you a chance to share and understand best practice procedures to minimise the damage of a hypothetical contamination.

Who should attend:

Professionals in Viral Safety, Quality Control, Quality Assurance, Downstream Processing, Microbiologists.

TESTIMONIALS

It was very valuable to have an overview about techniques which can be used and which basics are needed for this. It showed me that other pharmaceutical companies are faced with the same problems and to exchange on this
Susanne Tollar, Solvay Pharmaceuticals
Good balance between technical presentations & practical ones
Nuria Cubel Sune, Lab Esteve
Interesting & willing to create discussion and to elaborate the presented themes. It was valuable
Isabel Sequeira, Hovione Farmaciencia SA
I learned some interesting new technologies & approaches
Nuno Silva, Hovione Farmaciencia SA
Good to meet the main players and have made contacts that I would not have made otherwise.
Chris Christodoulou, Medimmune
Sponsor Media Partners
Pall Animated_Media

[ Register Now ]